NEGGRAM
LOE ApproachingNDAORALTABLETPriority Review
Approved
Mar 1964
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NEGGRAM is an oral small-molecule tablet approved in 1964 by Sanofi under NDA status. The specific mechanism of action and indication are not documented in available data, limiting current clinical characterization. This legacy product operates in a mature market segment with established safety and tolerability profiles.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting transition planning and potential team restructuring as exclusivity erodes.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NEGGRAM currently shows zero linked job openings, reflecting its legacy status and minimal growth investment. Career opportunities center on market defense, generic transition management, and potential divestiture planning rather than growth or innovation.
Brand ManagerMarket Access Manager
Worked on NEGGRAM at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.